Biomoda, Inc., Maker of Early Lung Cancer Detection Test, Retains Northport Associates for Government Relations and Public Affairs Services

Albuquerque, NM January 17, 2006 -- Biomoda, Inc. of Albuquerque, NM, maker of early lung cancer detection testing and other cancer diagnostic technology, announced its agreement with Northport Associates to direct Biomoda’s government and public affairs efforts. Northport will spearhead Biomoda’s state and federal lobbying to secure funding for its programs to screen military personnel and veterans for lung cancer using Biomoda’s proprietary assay. Biomoda trades on NASDAQ's OTC Bulletin Board: ticker symbol “BMOD”.

“We are extremely proud to assist Biomoda when speaking with state and federal lawmakers in support of the company’s medical breakthrough technology,” said Maria Zannes, a principal of Northport Associates. Ms. Zannes, an attorney, and Northport principal Thomas Peacock will manage communications and outreach. Each have more than 30 years experience on Capitol Hill, the White House and private industry directing public policy issues.

“Over the next six years, the Lung Cancer Alliance estimates that a million Americans will die from lung cancer,” said Mr. Peacock, who will be managing federal communication with the Congress and the Administration. “Biomoda’s technology can greatly help in the battle against cancer by providing early detection for better treatment. Several proposals under legislative review will work with active military and veterans to provide broad-base cancer screening for these brave men and women who now face an even great risk from lung cancer.”

Mayo Clinic, one of the premier healthcare and research institutions in the world and the Company are jointly conducting a broad validation study of Biomoda’s patented technology, a non-invasive cytology based lung cancer diagnostic assay. Biomoda’s technology is based on a patented porphyrin application that preferentially binds to cancerous or aberrant cells extracted from lung sputum samples. Cancerous cells glow red under fluorescent light to allow detection under a microscope.

The patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.

Lung cancer claims more lives than any other cancer. The expected 5-year survival rate for all patients combined in whom lung cancer is diagnosed is 15 percent and by contrast, the 5-year survival rate for cases detected when the disease is still localized is 50 percent. At the present time, only 16 percent of lung cancer cases are diagnosed at this early stage.

“Safe Harbor” Statement: This press release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from expectations contained herein. Biomoda is under no obligation to (and expressly disclaims any such obligation) to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise